Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer (NCT07215910)
Phase III Trial of Radiotherapy Followed by Adjuvant Temozolomide in Combination With the IDH Inhibitor Vorasidenib vs Placebo in IDH-Mutated Newly-Diagnosed Grade 3 Astrocytomas
🩺 Plain-English Summary (8th-Grade Level)
This phase III trial compares the effect of vorasidenib to placebo in combination with usual treatment, temozolomide, in treating patients with newly diagnosed grade 3 astrocytoma after radiation. Temozolomide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid and may kill tumor cells and slow down or stop tumor growth. Vorasidenib citrate blocks the proteins made by the mutated IDH1 and IDH2 genes, which may help keep tumor cells from growing. It is a type of enzyme inhibitor and a type of targeted therapy. Adding vorasidenib to the usual treatment, temozolomide, may be more effective than temozolomide alone in treating patients with newly diagnosed grade 3 astrocytoma after radiation therapy.
Who can join: Review the eligibility criteria below.
Location: City of Hope Comprehensive Cancer Center — Duarte, California
Age range: 12 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (97 Sites)
Showing the first 25 of 97 sites.
- City of Hope Comprehensive Cancer Center — Duarte, California
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care — Irvine, California
- UC Irvine Health/Chao Family Comprehensive Cancer Center — Orange, California
- University of California Davis Comprehensive Cancer Center — Sacramento, California
- Yale University — New Haven, Connecticut
- Smilow Cancer Hospital Care Center-Trumbull — Trumbull, Connecticut
- Smilow Cancer Hospital Care Center - Waterford — Waterford, Connecticut
- Helen F Graham Cancer Center — Newark, Delaware
- Medical Oncology Hematology Consultants PA — Newark, Delaware
- OSF Saint Joseph Medical Center — Bloomington, Illinois
- Illinois CancerCare-Bloomington — Bloomington, Illinois
- Illinois CancerCare-Canton — Canton, Illinois
- Illinois CancerCare-Carthage — Carthage, Illinois
- University of Illinois — Chicago, Illinois
- Illinois CancerCare-Eureka — Eureka, Illinois
- NorthShore University HealthSystem-Evanston Hospital — Evanston, Illinois
- Illinois CancerCare-Galesburg — Galesburg, Illinois
- NorthShore University HealthSystem-Glenbrook Hospital — Glenview, Illinois
- NorthShore University HealthSystem-Highland Park Hospital — Highland Park, Illinois
- Illinois CancerCare-Kewanee Clinic — Kewanee, Illinois
- Illinois CancerCare-Macomb — Macomb, Illinois
- Illinois CancerCare-Ottawa Clinic — Ottawa, Illinois
- Illinois CancerCare-Pekin — Pekin, Illinois
- Illinois CancerCare-Peoria — Peoria, Illinois
- OSF Saint Francis Radiation Oncology at Peoria Cancer Center — Peoria, Illinois
📞 Contact the Study Coordinator
Phone: (773) 834-4518
Email: alevasseur@bsd.uchicago.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
Explore by condition: All Astrocytoma, IDH-Mutant, Grade 3 clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.